Richard Zelman MD

 Richard Zelman MD



Comments

Post a Comment

Popular posts from this blog

Richard Zelman MD | Zelmancardiology.com

 Richard Zelman  MD is an esteemed Internist, Cardiologist and Interventional Cardiologist who has performed almost two thousand minimally invasive heart valve procedures, launched four cardiac catheterization laboratories, and successfully built the coalition that brought the very first community hospital open-heart cardiac surgical programs and coronary interventional programs to Massachusetts. He is considered one of the preeminent experts in his field of structural heart, interventional coronary and peripheral vascular catheter procedures. He is also extremely experienced in transthoracic and transesophageal echocardiography, nuclear cardiology, and implantable devices. Dr. Zelman is also a prolific clinical researcher and Primary Investigator, whose research has been published in numerous clinical journals, and was named one of America’s Top Doctors® by Castle Connolly Medical, Ltd.
Read more

Richard Zelman MD

  Richard Zelman MD Dr. Richard Zelman, MD is a cardiology specialist in Hyannis, MA and has 40 years experience. They graduated from University Of Texas Health Sciences Center At San Antonio Long School Of Medicine. They currently practice at Ascension Medical Group Genesys Heart Center and are affiliated with Cape Cod Hospital and Falmouth Hospital. At present, Dr. Zelman received an average rating of 4.5/5 from patients and has been reviewed 11 times. Their office is not accepting new patients. Dr. Zelman is board certified in Cardiovascular Disease and accepts multiple insurance plans.
Read more

Richard Zelman MD | Current Advances and Clinical Trials

Image
The field of cardiac cell therapy is rapidly evolving, with several ongoing clinical trials assessing the safety and efficacy of various cell-based approaches. Dr. Zelman points to some of the most promising studies:   The C-CURE Trial: This trial investigated the use of cardiac progenitor cells in patients with chronic heart failure. Results showed that patients who received cell therapy experienced significant improvements in heart function and exercise capacity compared to those who received standard care.   The CHART-1 Trial: This trial evaluated the safety and efficacy of cardiopoietic stem cells in heart failure patients. Although the primary endpoint was not met, a subgroup analysis suggested potential benefits in specific patient populations, underscoring the need for more targeted approaches.
Read more